Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Medical University of Gdansk
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07270263CT.gov Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies | — | Recruiting | — | — | — |
NCT02468102CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden) | — | Completed | — | — | — |
NCT01947985CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands) | — | Completed | — | — | — |
NCT01947959CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany) | — | Completed | — | — | — |
NCT01947998CT.gov Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pulmonary Embolism
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivaroxaban (this asset) | Medical University of Gdansk | N/A | D · 30 |
| Apixaban | Medical University of Gdansk | P3 | BB |
| Tranexamic Acid | Albert Einstein College of Medicine | P4 | BB |
| Fondaparinux | Johns Hopkins University | P2 | BB |
| Heparin | Johns Hopkins University | P4 | B |
| Enoxaparin | Medical University of Gdansk | P1/2 | B |
| Helium | Thunder Bay Regional Health Research Institute | Early P1 | C |
| Sulfur Hexafluoride | Thunder Bay Regional Health Research Institute | Early P1 | C |
| Perflutren | Thunder Bay Regional Health Research Institute | Early P1 | C |
+5 more in the Pulmonary Embolism cohort
Other indications for Rivaroxaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P4 | BBB · 79 |
| Hemorrhagic Disease | — | P4 | BBB · 76 |
| Thrombotic Disease | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivaroxaban in Pulmonary Embolism. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivaroxaban-pulmonary-embolism
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →